Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on First-Line VEGFR-Targeted Therapy
Phase of Trial: Phase II
Latest Information Update: 05 Apr 2018
At a glance
- Drugs Cabozantinib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 07 Mar 2018 Status changed from active, no longer recruiting to completed.
- 21 Aug 2017 Status changed from suspended to active, no longer recruiting.